GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

AbbVie and FutureGen Enter License Agreement for Advanced Inflammatory Bowel Disease Therapy

NextEdge Admin

15 Jun 2024

3 min 3 sec

AbbVie and FutureGen Biopharmaceutical (Beijing) Co., Ltd. have entered into a significant license agreement to develop FG-M701, a next-generation TL1A antibody designed for treating inflammatory bowel disease (IBD). FG-M701, a fully human monoclonal antibody targeting TL1A, aims to offer enhanced therapeutic benefits compared to existing therapies by potentially improving efficacy and requiring less frequent dosing.

Jonathon Sedgwick, Ph.D., senior vice president of discovery research at AbbVie, highlighted the increasing prevalence of IBD and the limited effectiveness of current treatments. He expressed AbbVie's commitment to advancing transformative therapies that can help more patients achieve remission from autoimmune diseases like ulcerative colitis and Crohn's disease. The collaboration with FutureGen is seen as pivotal in progressing FG-M701 towards addressing these unmet medical needs.

FutureGen's founder and CEO, Zhaoyu Jin, Ph.D., emphasized AbbVie's global leadership in inflammation and autoimmune therapies, positioning them as an ideal partner to accelerate FG-M701's development and commercialization. FutureGen's proprietary Structure-based Targeted Evolution Platform (STEP) was instrumental in designing FG-M701, showcasing their capability to generate potentially superior therapeutic candidates.

Under the agreement, AbbVie gains exclusive global rights to develop, manufacture, and market FG-M701. FutureGen stands to receive $150 million upfront and near-term milestone payments, with potential additional payments totaling up to $1.56 billion linked to clinical development, regulatory milestones, and commercial achievements. FutureGen will also receive tiered royalties on net sales.

AbbVie's mission focuses on pioneering medicines across key therapeutic areas such as immunology, oncology, neuroscience, and eye care, alongside products in the Allergan Aesthetics portfolio. FutureGen, on the other hand, is dedicated to advancing innovative biologics for cancer, immune diseases, and other conditions, leveraging advanced technologies like structural biology and AI to accelerate drug development.

The collaboration underscores a shared commitment to pushing the boundaries of treatment possibilities in IBD and potentially other autoimmune disorders, leveraging cutting-edge science and strategic partnerships to benefit patients worldwide.